• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

    6/10/24 12:15:17 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGEN alert in real time by email
    SC 13G/A 1 tv0015-agenusinc.htm SCHEDULE 13G/A agenusinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  Agenus Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  00847G804

    Date of Event Which Requires Filing of this Statement: May 31, 2024

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  00847G804

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    11,964

    7.  SOLE DISPOSITIVE POWER

    2,131,421

    8.  SHARED DISPOSITIVE POWER

    18,436

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,149,857

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.24%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Agenus Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3 Forbes Road
    Lexington, MA 02421-7305

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    00847G804

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  June 10, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $AGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGEN

    DatePrice TargetRatingAnalyst
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    7/18/2024Outperform → Mkt Perform
    William Blair
    7/18/2024$9.00Buy → Neutral
    H.C. Wainwright
    6/6/2023$8.00Outperform
    Robert W. Baird
    6/6/2023$60.00 → $80.00Outperform
    Robert W. Baird
    2/28/2023$8.00Buy
    H.C. Wainwright
    9/28/2022$5.00Outperform
    SMBC Nikko
    3/2/2022$12.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu

      4/29/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

      Initial results from NEOASIS demonstrate BOT/BAL efficacy in the neoadjuvant setting across multiple MSS and MSI-H solid tumors Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficient (dMMR/MSI-H) solid tumors. These findings include the first reported outcomes with BOT/BAL outside colo

      4/28/25 3:30:00 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

      Durable responses observed in heavily pretreated HCC patients who progressed on approved immunotherapies Agenus Inc. (NASDAQ:AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The HCC cohort comprised patients with difficult-to-treat disease who had progressed following standard treatments, including approved immunotherapies. "The treatment of patients with advanced HCC who progressed on immune

      4/25/25 1:05:00 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Buell Jennifer was granted 581 shares, increasing direct ownership by 3% to 19,738 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/6/25 5:21:12 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Armen Garo H was granted 5,260 shares, increasing direct ownership by 3% to 181,060 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/5/25 4:05:04 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Buell Jennifer was granted 869 shares, increasing direct ownership by 5% to 19,157 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/5/25 4:05:05 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Agenus Announces Appointment of Tom Harrison to Board of Directors

      Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

      8/8/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

      Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

      6/17/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Expands Executive Leadership Team

      Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

      7/20/23 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      2/15/24 6:59:48 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      11/17/23 4:22:11 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Financials

    Live finance-specific insights

    See more
    • Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu

      4/29/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

      Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati

      3/11/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/886193189.

      2/25/25 8:26:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Agenus Inc.

      DEFR14A - AGENUS INC (0001098972) (Filer)

      5/5/25 4:15:11 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Agenus Inc.

      DEF 14A - AGENUS INC (0001098972) (Filer)

      4/30/25 4:05:22 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Agenus Inc.

      PRE 14A - AGENUS INC (0001098972) (Filer)

      4/18/25 4:30:17 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 7:58:18 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 9:21:26 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      6/10/24 12:15:17 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agenus downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

      7/19/24 7:27:15 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by William Blair

      William Blair downgraded Agenus from Outperform to Mkt Perform

      7/18/24 1:59:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00

      7/18/24 12:35:32 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care